Skip to main content
Top

Insights into the complex relationship between pain and imaging-detected structural damage in knee osteoarthritis

Abstract

Knee osteoarthritis (OA) is a leading cause of chronic pain and disability, yet the relationship between imaging-detected structural damage and clinical pain remains still unclear. This persistent pain–structure discordance limits the effectiveness of current treatments and poses major challenges for clinical trial design and the development of disease-modifying OA drugs. Advances in imaging particularly MRI-based scoring systems have improved characterization of cartilage, bone, synovial, and meniscal pathology, but morphologic imaging alone cannot capture the neurobiological processes that shape the pain experience. This review summarizes pathophysiological changes and pain mechanism related to OA, followed by a review of pain assessment tools, a summary of our current understanding of the association between structural damage and pain experience in knee OA. Finally, we discuss emerging imaging tools, including positron emission tomography, which may help visualize inflammatory and neurobiological processes in both the knee joint and the brain.
Title
Insights into the complex relationship between pain and imaging-detected structural damage in knee osteoarthritis
Authors
David Ferreira Branco
C. Kent Kwoh
Theresa Patzer
Marco L. Loggia
Ali Guermazi
Mohamed Jarraya
Publication date
01-04-2026
Publisher
Springer Berlin Heidelberg
Published in
Skeletal Radiology
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-026-05204-4
This content is only visible if you are logged in and have the appropriate permissions.

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

1.75 AMA PRA Category 1 Credits

Explore using biomarker testing to interpret results and guide treatment strategies through an interactive patient simulation and unique educational escape rooms.

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Lilly
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME, Alzheimer’s disease in the biomarker era: preparing the multidisciplinary care team/© Springer Healthcare IME